Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (141-150 of 289) with videos related to

Pageof 29
Sort By:
Journal of Translational Medicine|August 16, 2022
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsMarzia Del Re, Stefania Crucitta, Federico Paolieri, et al.
Journal of Global Oncology|September 28, 2018
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective RegistryHideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, et al.
Cancer|October 21, 2006
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III StudyEmilio Bajetta, Giuseppe Procopio, Laura Catena, et al.
The Journal of Clinical Endocrinology and Metabolism|September 15, 2016
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical StudyChiara Fiorentini, Martina Fragni, Paola Perego, et al.
Clinical Genitourinary Cancer|June 15, 2019
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell CarcinomaGiuseppe Procopio, Aristotelis Bamias, Manuela Schmidinger, et al.
Tumori|August 2, 2022
Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacyNicola Nicolai, Sebastiano Nazzani, Antonio Tesone, et al.
Expert Review of Proteomics|March 1, 2014
Stratification of clear cell renal cell carcinoma by signaling pathway analysisMattia Cremona, Virginia Espina, Dario Caccia, et al.
Clinical Genitourinary Cancer|November 7, 2018
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 StudyCristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, et al.
Frontiers in Oncology|September 2, 2022
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitorsGiandomenico Roviello, Martina Catalano, Ugo De Giorgi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2025
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi studyViktor Grünwald, Axel Bex, Sylvie Rottey, et al.
Pageof 29

Showing results (141-150 of 289) with videos related to

Sort By:
Pageof 29
Journal of Translational Medicine|August 16, 2022
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsMarzia Del Re, Stefania Crucitta, Federico Paolieri, et al.
Journal of Global Oncology|September 28, 2018
Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective RegistryHideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, et al.
Cancer|October 21, 2006
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III StudyEmilio Bajetta, Giuseppe Procopio, Laura Catena, et al.
The Journal of Clinical Endocrinology and Metabolism|September 15, 2016
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical StudyChiara Fiorentini, Martina Fragni, Paola Perego, et al.
Clinical Genitourinary Cancer|June 15, 2019
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell CarcinomaGiuseppe Procopio, Aristotelis Bamias, Manuela Schmidinger, et al.
Tumori|August 2, 2022
Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacyNicola Nicolai, Sebastiano Nazzani, Antonio Tesone, et al.
Expert Review of Proteomics|March 1, 2014
Stratification of clear cell renal cell carcinoma by signaling pathway analysisMattia Cremona, Virginia Espina, Dario Caccia, et al.
Clinical Genitourinary Cancer|November 7, 2018
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 StudyCristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, et al.
Frontiers in Oncology|September 2, 2022
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitorsGiandomenico Roviello, Martina Catalano, Ugo De Giorgi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2025
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi studyViktor Grünwald, Axel Bex, Sylvie Rottey, et al.
Pageof 29